Natco Pharma plans to launch generic Risdiplam pending Delhi High Court decision, offering discounts to patients.

Natco Pharma updates on Risdiplam launch in India, Delhi High Court denies Roche's injunction plea, pricing set at ₹15,900.

The company said it has decided to price its version of Risdiplam product at Rs 15,900, and further added that it intends to ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

The stock rose 2.95 per cent to hit a high of Rs 789. It was last seen trading 1.44 per cent up at Rs 777.45. At this price, ...

The Company has received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market. The Company wishes to clarify ...

Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., and Cipla Ltd. share prices dragged the NSE Nifty Pharma index ...

The NSE Nifty 50 ended 345.65 points or 1.49% down at 22,904.45, and the BSE Sensex closed 930.67 points or 1.22% lower at 73 ...

The Supreme Court of India (SCI) has issued notice to Swiss pharma major F Hoffmann-La Roche Ltd, the manufacturer of spinal muscular atrophy (SMA) drug risdiplam and asked the company whether the ...

Telangana: Natco Pharma has announced the superannuation of Dr Ramesh Dandala, Executive Vice President - Technology Transfer ...